Clinicopathological Characteristics and Prognosis Analysis of Stage IB Non-small Cell Lung Cancer

Clinicopathological Characteristics and Prognosis Analysis of Stage IB Non-small Cell Lung Cancer：A Retrospective Real World Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05979623

Enrollment

971

Registered

2023-08-07

Start date

2016-01-31

Completion date

2022-12-31

Last updated

2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage IB Non-Small Cell Lung Carcinoma

Brief summary

The goal of this observation study is to learn about clinicopathological characteristics and prognostic factors of stage IB NSCLC. The main question it aims to answer is wheather there is relationship between newly proposed clinicopathological features and the prognosis of stage IB NSCLC .The postoperative pathological and follow-up information of participants will be used for subsequent analysis.

Detailed description

A total of 971 NSCLC patients with pathological stage IB resected by surgery (R0) from January 2016 to December 2020 at Zhongshan Hospital of Fudan University were reviewed. The primary endpoint is RFS (recurrence-free survival) and OS (overall survival) is the secondary endpoint. The baseline characteristics of the patients were obtained statistically, and factors affecting the prognosis of patients with stage IB NSCLC were analyzed using survival analysis and Cox proportional hazard models. The characteristics of the patients include pathological type, STAS, GGO, gene mutation, and postoperative adjuvant chemotherapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* It was confirmed by histopathology as primary non-small cell lung cancer, and the pathological type was LUSC or LUAD; * According to the 8th edition of TNM clinical staging standards, it is determined as IB stage * No treatment was performed for the primary lesion of lung cancer before surgery; * No history of other malignant tumors before surgery; * Detailed clinical and pathological information, complete survival data, and no missing follow-up data.

Exclusion criteria

* The postoperative histopathological types include non-scale and non adenocarcinoma, such as lung adenosquamous cell carcinoma, large cell lung cancer, or lung sarcomatoid carcinoma; * Multiple lesion staging surgery; * History of merging with other malignant tumors * Having preoperative treatment; * Missing follow-up information.

Design outcomes

Primary

Measure	Time frame	Description
RFS	5 years	recurrence-free survival

Secondary

Measure	Time frame	Description
OS	5 years	overall survival

Countries

China

Outcome results